# Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis

> **NCT00665925** · PHASE2 · COMPLETED · sponsor: **Rigel Pharmaceuticals** · enrollment: 457 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Fostamatinib disodium (R935788)
- **DRUG:** Fostamatinib disodium (R935788)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00665925
- **Lead sponsor:** Rigel Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 457 (ACTUAL)
- **Last updated:** 2016-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00665925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00665925, "Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00665925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*